Get the Stockscreener App
23.83
1.27%
0.30
After Hours:
23.83
Acadia Pharmaceuticals Inc stock is traded at $23.83, with a volume of 1.62M.
It is up +1.27% in the last 24 hours and up +10.48% over the past month.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
See More
Previous Close:
$23.53
Open:
$23.305
24h Volume:
1.62M
Relative Volume:
0.76
Market Cap:
$3.99B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
132.39
EPS:
0.18
Net Cash Flow:
$80.53M
1W Performance:
+3.38%
1M Performance:
+10.48%
6M Performance:
+27.71%
1Y Performance:
+25.29%
1-Day Range:
$23.26
$24.06
1-Week Range:
$22.40
$24.06
52-Week Range:
$13.40
$25.23
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
23.83 | 3.94B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-12-24 | Reiterated | Needham | Buy |
| Jan-30-24 | Initiated | Robert W. Baird | Outperform |
| Jan-24-24 | Upgrade | Needham | Hold → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
| Oct-17-23 | Initiated | UBS | Buy |
| Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
| Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Jun-10-21 | Initiated | Berenberg | Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
| Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-21 | Downgrade | Stifel | Buy → Hold |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Initiated | Morgan Stanley | Overweight |
| Jul-07-20 | Upgrade | Stifel | Hold → Buy |
| Apr-16-20 | Initiated | Jefferies | Buy |
| Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Dec-16-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-23-19 | Reiterated | Needham | Buy |
| Dec-10-18 | Initiated | Canaccord Genuity | Hold |
| Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-09-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Initiated | Stifel | Hold |
| Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
What makes ACADIA Pharmaceuticals Inc. stock price move sharplyDaily Trading Tips That Work - jammulinksnews.com
Nektar soars on atopic dermatitis data, leads drug developer gainers in Q2 - BioWorld MedTech
Candlestick signals on ACADIA Pharmaceuticals Inc. stock todayROI Boosting Trade Opportunity Calendar Published - metal.it
What are the technical indicators suggesting about ACADIA Pharmaceuticals Inc.Expert Picks Data Feed For Consistent Profits - jammulinksnews.com
How many analysts rate ACADIA Pharmaceuticals Inc. as a “Buy”Real Time Insights For 2025 - jammulinksnews.com
What is the risk reward ratio of investing in ACADIA Pharmaceuticals Inc. stockExpert Picks Data Feed From AI Tools - jammulinksnews.com
Does ACADIA Pharmaceuticals Inc. stock perform well during market downturnsChart Pattern Strategy To Watch Now - jammulinksnews.com
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Trend analysis for ACADIA Pharmaceuticals Inc. this weekFree Daily Top Performing Stock Insights - Newser
ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $34.00 at JPMorgan Chase & Co. - MarketBeat
Published on: 2025-07-28 18:07:24 - metal.it
Is ACADIA Pharmaceuticals Inc. stock overvalued or undervaluedFree Investment Risk Control - jammulinksnews.com
What is ACADIA Pharmaceuticals Inc. company’s growth strategyExplosive market performance - jammulinksnews.com
ACADIA Pharmaceutical: ACP-101 Read-Out Is Not Fully Priced In (NASDAQ:ACAD) - Seeking Alpha
What is the dividend policy of ACADIA Pharmaceuticals Inc. stockConsistent high-performance stocks - jammulinksnews.com
What institutional investors are buying ACADIA Pharmaceuticals Inc. stockOutstanding stock performance - jammulinksnews.com
Is it the right time to buy ACADIA Pharmaceuticals Inc. stockGrow your portfolio with growth-oriented stocks - jammulinksnews.com
How ACADIA Pharmaceuticals Inc. stock performs during market volatilityFree Exclusive Access to Stock Gurus - metal.it
Why ACADIA Pharmaceuticals Inc. stock attracts strong analyst attentionBreakout Momentum Stocks - metal.it
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - 富途牛牛
What risks could impact ACADIA Pharmaceuticals Inc. stock performanceFree Investment Risk Control - jammulinksnews.com
ACADIA Pharmaceuticals Inc. Stock Analysis and ForecastDynamic profit expansion - PrintWeekIndia
Is ACADIA Pharmaceuticals Inc. a good long term investmentConsistent high-performance stocks - PrintWeekIndia
What drives ACADIA Pharmaceuticals Inc. stock priceHigh-yield portfolio picks - PrintWeekIndia
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025 - BioSpace
What analysts say about ACADIA Pharmaceuticals Inc. stockPowerful profit generation - Autocar Professional
BofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)’s Price Target To $23, Maintains Neutral Rating - MSN
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):